359 related articles for article (PubMed ID: 15520073)
21. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
[TBL] [Abstract][Full Text] [Related]
22. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation.
Mangel J; Buckstein R; Imrie K; Spaner D; Franssen E; Pavlin P; Boudreau A; Pennell N; Combs D; Berinstein NL
Ann Oncol; 2003 May; 14(5):758-65. PubMed ID: 12702531
[TBL] [Abstract][Full Text] [Related]
24. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.
Chakhachiro ZI; Saliba RM; Okoroji GJ; Korbling M; Alousi AM; Betul O; Anderlini P; Ciurea SO; Popat U; Champlin R; Samuels BI; Medeiros LJ; Bueso-Ramos C; Khouri IF
Cancer; 2013 Sep; 119(18):3318-25. PubMed ID: 23775587
[TBL] [Abstract][Full Text] [Related]
25. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.
Till BG; Gooley TA; Crawford N; Gopal AK; Maloney DG; Petersdorf SH; Pagel JM; Holmberg L; Bensinger W; Press OW
Leuk Lymphoma; 2008 Jun; 49(6):1062-73. PubMed ID: 18452065
[TBL] [Abstract][Full Text] [Related]
26. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.
Kasamon YL; Jones RJ; Brodsky RA; Fuchs EJ; Matsui W; Luznik L; Powell JD; Blackford AL; Goodrich A; Gocke CD; Abrams RA; Ambinder RF; Flinn IW
Ann Oncol; 2010 Jun; 21(6):1203-1210. PubMed ID: 19880437
[TBL] [Abstract][Full Text] [Related]
27. Controversies in the treatment of lymphoma with autologous transplantation.
Moskowitz AJ; Moskowitz CH
Oncologist; 2009 Sep; 14(9):921-9. PubMed ID: 19737999
[TBL] [Abstract][Full Text] [Related]
28. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Forstpointner R; Dreyling M; Repp R; Hermann S; Hänel A; Metzner B; Pott C; Hartmann F; Rothmann F; Rohrberg R; Böck HP; Wandt H; Unterhalt M; Hiddemann W;
Blood; 2004 Nov; 104(10):3064-71. PubMed ID: 15284112
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.
Ladetto M; Tavarozzi R; Zanni M; Evangelista A; Ferrero S; Tucci A; Botto B; Bolis S; Volpetti S; Zilioli VR; Puccini B; Arcari A; Pavone V; Gaidano G; Corradini P; Tani M; Cavallo F; Milone G; Ghiggi C; Pinto A; Pastore D; Ferreri AJM; Latte G; Patti C; Re F; Benedetti F; Luminari S; Pennese E; Bossi E; Boccomini C; Anastasia A; Bottelli C; Ciccone G; Vitolo U
Ann Oncol; 2024 Jan; 35(1):118-129. PubMed ID: 37922989
[TBL] [Abstract][Full Text] [Related]
30. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
31. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma.
Tam CS; Khouri IF
Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639
[TBL] [Abstract][Full Text] [Related]
32. Rituximab: enhancing outcome of autologous stem cell transplantation in non-Hodgkin's lymphoma.
Gisselbrecht C; Mounier N
Semin Oncol; 2003 Feb; 30(1 Suppl 2):28-33. PubMed ID: 12652462
[TBL] [Abstract][Full Text] [Related]
33. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
34. A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Morschhauser F; Recher C; Milpied N; Gressin R; Salles G; Brice P; Vey N; Haioun C; Colombat P; Rossi JF; Deconinck E; Lazreg F; Bergougnoux L; Delsol G; Attal M
Ann Oncol; 2012 Oct; 23(10):2687-2695. PubMed ID: 22767588
[TBL] [Abstract][Full Text] [Related]
35. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
[TBL] [Abstract][Full Text] [Related]
36. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.
Hess G; Keller U; Scholz CW; Witzens-Harig M; Atta J; Buske C; Kirschey S; Ruckes C; Medler C; van Oordt C; Klapper W; Theobald M; Dreyling M
Leukemia; 2015 Aug; 29(8):1695-701. PubMed ID: 25765545
[TBL] [Abstract][Full Text] [Related]
38. Autologous stem cell transplantation in patients with mantle cell lymphoma.
Oinonen R; Jantunen E; Itälä M; Lehtinen T; Kuittinen O; Franssila K; Wiklund T; Elonen E
Leuk Lymphoma; 2002 Jun; 43(6):1229-37. PubMed ID: 12152990
[TBL] [Abstract][Full Text] [Related]
39. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma.
Lazzarino M; Arcaini L; Bernasconi P; Alessandrino EP; Gargantini L; Cairoli R; Orlandi E; Astori C; Brusamolino E; Pagnucco G; Colombo AA; Calatroni S; Iacona I; Regazzi MB; Morra E
Br J Haematol; 2002 Jan; 116(1):229-35. PubMed ID: 11841421
[TBL] [Abstract][Full Text] [Related]
40. A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
Joyce RM; Regan M; Ottaway J; Umiel T; Tetreault JC; Levine J; McDermott D; Hurley D; Giallombardo N; Smith T; Lamontagne D; Uhl L; Avigan D
Ann Oncol; 2003; 14 Suppl 1():i21-7. PubMed ID: 12736227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]